What to know
- RF microneedling has risks beyond a simple device label.
- Discuss the FDA communication with the treating professional.
- Confirm the component, provider experience and follow-up process.
What the FDA communication says
In its October 2025 safety communication, the FDA described reports of serious complications associated with certain uses of RF microneedling. Reported problems included burns, scarring, fat loss, disfigurement and nerve damage; some required medical or surgical intervention. These are significant risks to discuss before deciding on treatment.
The communication does not, by itself, establish that every RF device has been recalled or that a particular patient will experience a complication. It does mean that general claims of no risk or an assured easy recovery would be inappropriate. Device-specific information and an individual assessment remain necessary.
Sources: FDA: RF microneedling safety communication; FDA: Microneedling devices; Cutera: Secret DUO; Chicago Medspa service information
Identify the treatment component
Cutera describes Secret DUO as a platform with RF microneedling and a separate 1540 nm fractional erbium-glass laser component. Ask which component is proposed and why. A photograph or video of the laser handpiece does not demonstrate the microneedling procedure, and the two components should not be conflated.
The FDA advises choosing a licensed healthcare provider with relevant training and experience. Useful questions include who will perform the treatment, what experience they have with that device and application, and how the clinic discusses possible complications and follow-up. Brand ownership alone does not answer these questions.
Sources: FDA: RF microneedling safety communication; FDA: Microneedling devices; Cutera: Secret DUO; Chicago Medspa service information
Make the risk discussion specific
Ask the provider to explain the intended treatment area, expected limitations and alternatives, including choosing not to proceed. Your health history and prior procedures belong in the clinical assessment. An online description cannot decide whether the procedure is appropriate for you or specify a safe energy setting.
Before treatment, understand how to reach the clinical team and what written instructions you will receive. This article explains the scope of the safety communication; it does not provide a complication diagnosis or an individual treatment plan. The linked FDA communication is the primary source for the agency's current information.
Sources: FDA: RF microneedling safety communication; FDA: Microneedling devices; Cutera: Secret DUO; Chicago Medspa service information
Sources and further reading
- FDA: RF microneedling safety communication
- FDA: Microneedling devices
- Cutera: Secret DUO
- Chicago Medspa service information
Manufacturer descriptions explain the product or technology. They do not replace an individual assessment or your provider’s instructions.